1-3 of 3
Jean-Pierre Issa, M.D.
Close
Sort by
Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.
Journal: Blood
Blood (2006) 108 (11): 2652.
https://doi.org/10.1182/blood.V108.11.2652.2652
Published: 2006
Journal Articles

Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias.

Jaroslav Jelinek, M.D., Ph.D., Rajan Mannari, M.D., Jean-Pierre Issa, M.D.
Journal: Blood
Blood (2004) 104 (11): 1126.
https://doi.org/10.1182/blood.V104.11.1126.1126
Published: 2004
Journal Articles

Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q).

Ting Xi Liu, M.D., Ph.D., Michael Becker, M.D., Karl Hsu, M.D., Jaroslav Jelinek, M.D., Ph.D., Min Deng, M.D., Clara Bloomfield, M.D.4, Jean-Pierre Issa, M.D., Michael F. Clarke, M.D., A. Thomas Look, M.D.4
Journal: Blood
Blood (2004) 104 (11): 203.
https://doi.org/10.1182/blood.V104.11.203.203
Published: 2004